129 related articles for article (PubMed ID: 9500988)
1. Early inhibition of DNA synthesis in the developing rat cerebral cortex by the purine analogues olomoucine and roscovitine.
Yakisich JS; Sidén A; Idoyaga Vargas V; Eneroth P; Cruz M
Biochem Biophys Res Commun; 1998 Feb; 243(3):674-7. PubMed ID: 9500988
[TBL] [Abstract][Full Text] [Related]
2. Strong inhibition of replicative DNA synthesis in the developing rat cerebral cortex and glioma cells by roscovitine.
Yakisich JS; Vita MF; Siden A; Tasat DR; Cruz M
Invest New Drugs; 2010 Jun; 28(3):299-305. PubMed ID: 19390782
[TBL] [Abstract][Full Text] [Related]
3. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
[TBL] [Abstract][Full Text] [Related]
4. The cyclin-dependent kinase (cdk) inhibitors, olomoucine and roscovitine, alter the expression of a molluscan circadian pacemaker.
Krucher NA; Meijer L; Roberts MH
Cell Mol Neurobiol; 1997 Oct; 17(5):495-507. PubMed ID: 9353591
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
[TBL] [Abstract][Full Text] [Related]
6. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics.
Schutte B; Nieland L; van Engeland M; Henfling ME; Meijer L; Ramaekers FC
Exp Cell Res; 1997 Oct; 236(1):4-15. PubMed ID: 9344580
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
[TBL] [Abstract][Full Text] [Related]
8. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.
Edamatsu H; Gau CL; Nemoto T; Guo L; Tamanoi F
Oncogene; 2000 Jun; 19(27):3059-68. PubMed ID: 10871858
[TBL] [Abstract][Full Text] [Related]
9. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
David-Pfeuty T
Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of 6-DMAP, olomoucine and roscovitine on Xenopus oocytes and eggs.
Flament S; Bodart JF; Bertout M; Browaeys E; Rousseau A; Vilain JP
Zygote; 2000 Feb; 8(1):3-14. PubMed ID: 10840869
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors.
Atienza C; Elliott MJ; Dong YB; Yang HL; Stilwell A; Liu TJ; McMasters KM
Int J Mol Med; 2000 Jul; 6(1):55-63. PubMed ID: 10851267
[TBL] [Abstract][Full Text] [Related]
12. Early effects of protein kinase modulators on DNA synthesis in rat cerebral cortex.
Yakisich JS; Sidén A; Vargas VI; Eneroth P; Cruz M
Exp Neurol; 1999 Sep; 159(1):164-76. PubMed ID: 10486185
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis of central and peripheral neurons can be prevented with cyclin-dependent kinase/mitogen-activated protein kinase inhibitors.
Maas JW; Horstmann S; Borasio GD; Anneser JM; Shooter EM; Kahle PJ
J Neurochem; 1998 Apr; 70(4):1401-10. PubMed ID: 9523556
[TBL] [Abstract][Full Text] [Related]
14. Roscovitine inhibits ongoing DNA synthesis in human cervical cancer.
Vitali L; Yakisich JS; Vita MF; Fernandez A; Settembrini L; Siden A; Cruz M; Carminatti H; Casas O; Idoyaga Vargas V
Cancer Lett; 2002 Jun; 180(1):7-12. PubMed ID: 11911964
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases.
Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L
Bioorg Med Chem Lett; 1998 Apr; 8(7):793-8. PubMed ID: 9871543
[TBL] [Abstract][Full Text] [Related]
16. Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons.
Monaco EA; Beaman-Hall CM; Mathur A; Vallano ML
Biochem Pharmacol; 2004 May; 67(10):1947-64. PubMed ID: 15130771
[TBL] [Abstract][Full Text] [Related]
17. Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines.
Buquet-Fagot C; Lallemand F; Montagne MN; Mester J
Anticancer Drugs; 1997 Jul; 8(6):623-31. PubMed ID: 9300578
[TBL] [Abstract][Full Text] [Related]
18. Effects of cyclin-dependent kinase inhibitors on transcription and ocular circadian rhythm of Aplysia.
Sankrithi N; Eskin A
J Neurochem; 1999 Feb; 72(2):605-13. PubMed ID: 9930732
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.
Holcakova J; Muller P; Tomasec P; Hrstka R; Nekulova M; Krystof V; Strnad M; Wilkinson GW; Vojtesek B
PLoS One; 2014; 9(2):e89228. PubMed ID: 24586613
[TBL] [Abstract][Full Text] [Related]
20. CDK-inhibitor olomoucine inhibits cell death after exposure of cell lines to cytosine-arabinoside.
Papazisis KT; Geromichalos GD; Kouretas D; Dimitriadis KA; Kortsaris AH
Cancer Lett; 1999 Apr; 138(1-2):221-6. PubMed ID: 10378797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]